<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03351777</url>
  </required_header>
  <id_info>
    <org_study_id>REALM-1</org_study_id>
    <nct_id>NCT03351777</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of PR022 Topical Gel to Treat Mild-to-Moderate Atopic Dermatitis</brief_title>
  <official_title>Efficacy and Safety of PR022 Topical Gel to Treat Mild-to-Moderate Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Realm Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Realm Therapeutics, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether PR022 Topical Gels are safe and effective
      treatments for mild-to-moderate atopic dermatitis (AD).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 4, 2017</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change from Baseline to Day 29 in Eczema Area and Severity Index (EASI)</measure>
    <time_frame>29 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects who achieved success in Investigator's Static Global Assessment (ISGA), defined as a score of &quot;Clear&quot; (0) or &quot;Almost Clear&quot; (1) with a minimum 2-grade improvement at Day 29</measure>
    <time_frame>29 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with an ISGA score of &quot;Clear&quot; (0) or &quot;Almost Clear&quot; (1) at Day 29</measure>
    <time_frame>29 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with EASI-75 (≥ 75% improvement from Baseline) at Day 29</measure>
    <time_frame>29 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with EASI-50 (≥ 50% improvement from Baseline) at Day 29</measure>
    <time_frame>29 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from Baseline to Day 29 in body surface area (BSA) affected by AD</measure>
    <time_frame>29 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Day 29 in SCORing Atopic Dermatitis (SCORAD)</measure>
    <time_frame>29 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from Baseline to Day 29 in pruritus Numerical Rating Scale (NRS)</measure>
    <time_frame>29 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Day 29 in 5 dimensions of itch (5-D Itch) scale</measure>
    <time_frame>29 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Day 29 in Dermatology Life Quality Index (DLQI)</measure>
    <time_frame>29 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency counts and percentages of DLQI scores (scored 0 to 3) at Baseline and Day 29, as well as shift in DLQI scores from Baseline to Day 29</measure>
    <time_frame>29 Days</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in serum IgE titer and TARC concentration from Baseline to Day 29</measure>
    <time_frame>29 days</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>PR022 topical gel, 0.05%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Applied twice daily for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PR022 topical gel, 0.1%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Applied twice daily for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PR022 topical gel vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Applied twice daily for 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PR022</intervention_name>
    <description>Topical Gel</description>
    <arm_group_label>PR022 topical gel, 0.05%</arm_group_label>
    <arm_group_label>PR022 topical gel, 0.1%</arm_group_label>
    <arm_group_label>PR022 topical gel vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects 18 to 65 years of age

          -  EASI score ≤ 21 at baseline

          -  Diagnosis of mild-to-moderate (grade 2 or 3) AD according to the ISGA scale at
             Baseline

          -  BSA affected by AD: 5% to 20% at start of treatment

          -  Willing and able to apply study treatments as directed, comply with study
             instructions, and commit to attending all visits

          -  Willing and able to provide informed consent

          -  Use of adequate birth control, if of reproductive potential and sexually active

        Exclusion Criteria:

          -  Widespread AD requiring systemic therapy

          -  Use of any of the following treatments within the specified time periods prior to Day
             1

          -  Topical medications (topical antibiotics, topical corticosteroids, topical
             antifungals, topical antihistamines, topical retinoids, topical calcipotriene,
             tacrolimus, pimecrolimus, or other topical drug products for treatment of AD) or
             bleach bath within 2 weeks prior to Day 1

          -  Systemic agents (cyclosporine, systemic corticosteroids [oral and injectable;
             intranasal and inhaled corticosteroids are allowed if use is kept constant during the
             study], systemic antibiotics, immunomodulators or immunosuppressive therapies,
             interferon, cytotoxic drugs [e.g., methotrexate, cyclophosphamide, azathioprine], oral
             retinoids, systemic antifungals, tacrolimus) for the treatment of AD within 4 weeks
             prior to Day 1

          -  Ultraviolet (UV) therapy or use of a tanning booth/parlor within 6 weeks prior to Day
             1

          -  Biologic therapies within 12 weeks (or 5 half-lives) prior to Day 1

          -  Antihistamines within 5 days prior to Day 1 [stable regimens (consistent use ≥ 14 days
             before Day 1) of oral H1 antihistamines for non-AD lesion treatment will be allowed]

          -  Active or potentially recurrent dermatologic condition other than AD that may confound
             evaluation

          -  Congenital ichthyosis (note that subjects with ichthyosis vulgaris are permitted)

          -  Known allergy to any ingredients of the investigational product formulation

          -  Significant confounding conditions as assessed by Investigator

          -  Any condition that could interfere with any evaluation in the study

          -  Pregnancy or breast feeding

          -  Any reason which, in the opinion of the Investigator, interferes with the ability of
             the subject to participate in or complete the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Peters, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Realm</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Valerie Crossley</last_name>
    <phone>4843212700</phone>
    <email>Valerie@realmtx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kathy Goin</last_name>
    <email>kgoin@realmtx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Principal Investigator</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19148</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 20, 2017</study_first_submitted>
  <study_first_submitted_qc>November 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2017</study_first_posted>
  <last_update_submitted>December 19, 2017</last_update_submitted>
  <last_update_submitted_qc>December 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

